NDAINTRATRACHEALSUSPENSION
Approved
Mar 2012
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SURFAXIN (lucinactant) is a synthetic pulmonary surfactant suspension administered intratracheal for respiratory distress syndrome in premature infants. It replaces deficient endogenous surfactant to improve lung compliance and gas exchange. The drug is indicated for prevention of respiratory distress syndrome in premature infants at high risk.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30%), indicating stable commercial operations but potential margin pressure from established competitors in the neonatal surfactant market.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SURFAXIN has limited but focused career opportunity footprint with only 3 linked positions, predominantly in project management. Working on this product means involvement in operational efficiency, market maintenance, and healthcare system relationships within a stable niche market rather than growth-stage innovation.
Project Manager
Worked on SURFAXIN at Lee's Pharmaceutical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.